England OKs Routine Funding For Three COVID-19 Treatments But Rejects Five Others
Executive Summary
The clinical and cost-effectiveness of Paxlovid, RoActemra, Olumiant, Ronapreve, Lagevrio, Veklury, Xevudy and Evusheld are discussed in a draft guidance from England’s health technology assessment institute, which says it is ready to work with the companies whose products it has not recommended.
You may also be interested in...
Three COVID-19 Drugs Clear UK Funding Hurdle But Olumiant No Longer In The Running
NICE says it is the first health technology assessment body to look at the non-pandemic use of COVID-19 treatments. It is also planning to launch a consultation on a new process for updating its recommendations on such products with a view to making them available more quickly if new variants emerge.
Lilly Pulls EU Approval Application For Olumiant In COVID-19
The European Medicines Agency says it does not have enough data to justify the approval of Olumiant for hospitalized COVID-19 patients. The marketing authorization application for another product, Reata’s Imbarkyd for chronic kidney disease, has also been withdrawn.
Disappointment & Surprise But Not Giving Up: Companies Respond To English Funding Rejection For COVID-19 Treatments
MSD, Gilead, GSK, AstraZeneca and Roche told the Pink Sheet what they thought of draft guidance that the health technology assessment institute, NICE, published today, recommending against routine commissioning for five COVID-19 treatments.